Conotoxins: review and docking studies to determine potentials of conotoxin as an anticancer drug molecule

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Potassium channels, particularly HERG (human ether-à-go-go-related gene), are vital for cell proliferation.
• HERG protein concentration increases on the surface of cancer cells, unlike its low presence in brain and heart tissues.
• HERG activation drives cancer cell proliferation, and blocking it can inhibit this growth.

Purpose of the Study:

• To investigate the binding potential of κ-PVIIA, a conotoxin from Conus purpurascens venom, with the HERG K+ channel in tumor cells.
• To explore the interaction between the peptide toxin and the HERG protein, especially in cases of HERG mutation.
• To lay the groundwork for developing novel cancer therapeutics derived from conotoxins.

Main Methods:

• In silico docking studies were employed to analyze the binding of κ-PVIIA with the HERG K+ channel.
• Computational methods were used to study the binding of similar toxins with normal potassium channels.
• Structural analysis focused on the interaction site between the conotoxin and the HERG protein.

Main Results:

• Docking studies indicated that κ-PVIIA binds stably to the HERG protein.
• The peptide toxin interacts with the charged extracellular S5-P extracellular linker of the HERG protein.
• The binding suggests a specific interaction mechanism between the conotoxin and the HERG channel.

Conclusions:

• κ-PVIIA demonstrates stable binding to the HERG channel, suggesting its potential as a therapeutic lead.
• The interaction occurs at a specific extracellular domain of the HERG protein, offering a potential drug target site.
• Further wet laboratory validation is necessary to develop κ-PVIIA into a drug for treating certain cancers.